专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007148095A3 METHODS FOR DETERMINING A PROGNOSIS OF COLORECTAL CANCER 审中-公开
标题翻译：确定色素性癌症的方法
公开(公告)号：WO2007148095A3
公开(公告)日：2008-02-21
申请号：PCT/GB2007002316
申请日：2007-06-21
申请人： CANCER REC TECH LTD , HUTCHISON CHRISTOPHER , COX THOMAS , WILSON ROBERT , PRZYBORSKI STEFAN , VAN ENGELAND MANON , DE BRUINE ADRIAN
发明人： HUTCHISON CHRISTOPHER , COX THOMAS , WILSON ROBERT , PRZYBORSKI STEFAN , VAN ENGELAND MANON , DE BRUINE ADRIAN
IPC分类号： G01N33/574 , C07K16/00
CPC分类号： G01N33/57419
摘要： The invention provides methods for determining a prognosis of colorectal cancer in an individual comprising determining an A-type lamin status of an individual and using the A-type lamin status to determine the prognosis of the colorectal cancer, and more particularly for predicting outcomes of colorectal cancer in the individual such as the survival or mortality of the individual or the likelihood of recurrence of the colorectal cancer. Kits for use in carrying out these methods are also provided.
摘要翻译：本发明提供了确定个体中结肠直肠癌预后的方法，其包括确定个体的A型层状态，并使用A型层状态来确定结肠直肠癌的预后，更具体地，用于预测结肠直肠的结果个体中的癌症如个体的存活或死亡或结肠直肠癌复发的可能性。还提供了用于实施这些方法的试剂盒。

2. 发明申请

WO2007148095A8 METHODS FOR DETERMINING A PROGNOSIS OF COLORECTAL CANCER 审中-公开
标题翻译：确定色素性癌症的方法
公开(公告)号：WO2007148095A8
公开(公告)日：2009-07-16
申请号：PCT/GB2007002316
申请日：2007-06-21
申请人： CANCER REC TECH LTD , HUTCHISON CHRISTOPHER , COX THOMAS , WILSON ROBERT , PRZYBORSKI STEFAN , VAN ENGELAND MANON , DE BRUINE ADRIAN
发明人： HUTCHISON CHRISTOPHER , COX THOMAS , WILSON ROBERT , PRZYBORSKI STEFAN , VAN ENGELAND MANON , DE BRUINE ADRIAN
IPC分类号： G01N33/574 , C07K16/00
CPC分类号： G01N33/57419
摘要： The invention provides methods for determining a prognosis of colorectal cancer in an individual comprising determining an A-type lamin status of an individual and using the A-type lamin status to determine the prognosis of the colorectal cancer, and more particularly for predicting outcomes of colorectal cancer in the individual such as the survival or mortality of the individual or the likelihood of recurrence of the colorectal cancer. Kits for use in carrying out these methods are also provided.
摘要翻译：本发明提供了确定个体中结肠直肠癌预后的方法，其包括确定个体的A型层状态，并使用A型层状态来确定结肠直肠癌的预后，更具体地，用于预测结肠直肠的结果个体中的癌症如个体的存活或死亡或结肠直肠癌复发的可能性。还提供了用于实施这些方法的试剂盒。

3. 发明申请

WO2008084219A8 EPIGENETIC CHANGE IN SELECTED GENES AND CANCER 审中-公开
标题翻译：选择性基因和癌症的表观变化
公开(公告)号：WO2008084219A8
公开(公告)日：2008-12-18
申请号：PCT/GB2008000056
申请日：2008-01-09
申请人： ONCOMETHYLOME SCIENCES SA , BALDOCK SHARON CLAIRE , VAN ENGELAND MANON , DE BRUINE MANON ADRIAAN , GRIFFIOEN ARJAN , LOUWAGIE JOOST , BIERAU KATJA , BRICHARD GONTRAN , OTTO GAETAN , PENNING MAARTEN
发明人： VAN ENGELAND MANON , DE BRUINE MANON ADRIAAN , GRIFFIOEN ARJAN , LOUWAGIE JOOST , BIERAU KATJA , BRICHARD GONTRAN , OTTO GAETAN , PENNING MAARTEN
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/118 , C12Q2600/154 , C12Q2600/158 , C12Q2600/16
摘要： A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRPl, ADAM23, JPH3, SFRP2, APC, MGMT, TFPI2, BNIP3, FOXEl, SYNEl, S0X17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging or otherwise characterizing various diseases. The invention also relates to methods for identifying, diagnosing, staging or otherwise characterizing cancers, in particular gastrointestinal cancers such as colorectal cancers, gastric cancers and oesophageal cancers. The methods of the invention relate, inter alia, to isolating and analyzing the human DNA component from faecal samples and blood-based samples.
摘要翻译：检测样品中癌症的倾向性或发病率的方法包括检测选自NDRG4 / NDRG2亚家族基因，GATA4，OSMR，GATA5，SFRP1，ADAM23，JPH3，SFRP2或其组合中的至少一种基因的表观遗传变化， APC，MGMT，TFPI2，BNIP3，FOXE1，SYNE1，SOX17，PHACTR3和JAM3，其中表观遗传变化的检测表明癌症的倾向或癌症的发病。还描述了基于根据本发明的方法选择患者的用于确定癌症的合适治疗方案的药物遗传学方法和用于治疗癌症患者的方法。本发明还涉及收集，处理和分析样品，特别是体液样品的改进方法。这些方法可用于诊断，分期或以其他方式表征各种疾病。本发明还涉及用于鉴定，诊断，分期或以其他方式表征癌症的方法，特别是胃肠癌如结肠直肠癌，胃癌和食管癌。本发明的方法尤其涉及从粪便样品和血液样品中分离和分析人类DNA组分。

4. 发明申请

WO2007017065A2 ANGIOGENESIS INHIBITION 审中-公开
标题翻译：血管生成抑制
公开(公告)号：WO2007017065A2
公开(公告)日：2007-02-15
申请号：PCT/EP2006007092
申请日：2006-07-19
申请人： ONCOMETHYLOME SCIENCES SA , VAN ENGELAND MANON , GRIFFIOEN ARJAN W
发明人： VAN ENGELAND MANON , GRIFFIOEN ARJAN W
IPC分类号： G01N33/574 , C12Q1/68
CPC分类号： G01N33/57488 , C12Q1/6883 , C12Q1/6886 , C12Q2600/136 , G01N33/5064 , G01N33/57496 , G01N33/6893 , G01N2500/00 , G01N2800/102 , G01N2800/164 , G01N2800/20
摘要： Methods for determining angiogenesis associated with a disease in a subject include the steps of, in a suitable test sample, determining expression levels of at least one gene selected from junB and ICAM 1. A statistically significant decrease in, or low level of, expression of one or both of the genes indicates the presence of angiogenesis associated with the disease in the subject. Preferably, the test sample includes endothelial cells. The method may further include determining the expression of THBSl and/or IGFBP3. Methods of determining angiogenesis in a subject may also include determining the level of acetylated histone H3 in the promote region of the IGFBP3 gene in a test sample. Pharmaceutical compositions for use in inhibiting angiogenesis include a DNA methyltransf erase inhibitor together with a pharmaceutically acceptable carrier and are in a form suitable for metronomic dosing. They may alternatively or additionally include a component allowing targeting to endothelial cells. Methods of preventing or inhibiting angiogenesis associated with a disease in a subject involve administering a therapeutically effective amount of a DNA methyltransf erase inhibitor. Treatment regimes, microarrays and screening methods are also described.
摘要翻译：用于测定与受试者疾病相关的血管生成的方法包括以下步骤：在合适的测试样品中，确定至少一种选自junB和ICAM1的基因的表达水平。统计学上显着的降低或低水平的基因中的一个或两个表示与受试者中的疾病相关的血管发生的存在。优选地，测试样品包括内皮细胞。该方法还可以包括确定THBS1和/或IGFBP3的表达。确定受试者血管生成的方法还可以包括确定测试样品中IGFBP3基因的促进区中的乙酰化组蛋白H3的水平。用于抑制血管发生的药物组合物包括DNA甲基转移酶抑制剂和药学上可接受的载体，并且是适合于节律剂剂量的形式。它们可以或者另外包括允许靶向内皮细胞的成分。预防或抑制与受试者疾病相关的血管发生的方法包括给予治疗有效量的DNA甲基转移酶抑制剂。还描述了治疗方案，微阵列和筛选方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式